Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.090 | Biomarker | disease | BEFREE | The NY-ESO-1 knockdown may be considered for future clinical trials in MM. | 31489631 | 2020 | ||||
|
0.090 | AlteredExpression | disease | BEFREE | T cells collected from 25 HLA-A*02:01-positive patients with MM expressing NY-ESO-1 and/or LAGE-1 were activated, transduced with self-inactivating lentiviral vector encoding the NY-ESO-1<sup>c259</sup>TCR, and expanded in culture. | 31289029 | 2019 | ||||
|
0.090 | Biomarker | disease | BEFREE | NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease. | 28637663 | 2017 | ||||
|
0.090 | AlteredExpression | disease | BEFREE | However, NY-ESO-1 expression is usually very low or absent in some tumors such as breast cancer or multiple myeloma. | 26447882 | 2015 | ||||
|
0.090 | AlteredExpression | disease | BEFREE | NY-ESO-1-LAGE-1 TCR-engineered T cells were safe, trafficked to marrow and showed extended persistence that correlated with clinical activity against antigen-positive myeloma. | 26193344 | 2015 | ||||
|
0.090 | Biomarker | disease | BEFREE | In a murine xenograft model of NY-ESO-1(+) multiple myeloma, we observed tumor recurrence after adoptive transfer of CD8(+) T cells genetically redirected to the prototypic NY-ESO-1157-165 peptide presented by HLA-A*02:01. | 24451117 | 2014 | ||||
|
0.090 | Biomarker | disease | BEFREE | Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. | 22739387 | 2013 | ||||
|
0.090 | Biomarker | disease | BEFREE | SSX protein expression ranged from 13.5% of PCs in an SSX1/SSX4 co-expressor to as high as 88% of PCs in group A expressor, exceeding reported frequencies of NY-ESO-1 and MAGE in MM. | 16224274 | 2006 | ||||
|
0.090 | Biomarker | disease | BEFREE | Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. | 16267030 | 2005 |